• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

Poll

POLL: Which Recent FDA Update Was Most Exciting?

Author(s):

Dermatology Times Staff

Click here to answer this week's poll.

Baricitinib FDA Approved to Treat Alopecia Areata
Dupilumab FDA Approved for AD Patients 6 months to 5 years
TMB-001 Granted FDA Breakthrough Therapy Designation
FDA Grants Priority Review for Dupilumab sBLA for Adults with Prurigo Nodularis
Tapinarof Cream 1% is FDA Approved
Related Videos
infectious disease
Related Content
Delgocitinib Approved for Adults with Moderate to Severe CHE in Switzerland
November 14th 2024

Delgocitinib Approved for Adults with Moderate to Severe CHE in Switzerland

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics
September 23rd 2021

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics

PDUFA Date for Tapinarof 1% Cream in Atopic Dermatitis Pushed to 2025
November 5th 2024

PDUFA Date for Tapinarof 1% Cream in Atopic Dermatitis Pushed to 2025

The Cutaneous Connection
September 2nd 2021

The Cutaneous Connection: Episode 30- Impact of the JAK Inhibitor Approval Delays

Valisure's David Light Shares Insights Into Newly-Published Benzene and BPO Data
October 8th 2024

Valisure's David Light Shares Insights Into Newly-Published Benzene and BPO Data

BREAKING NEWS: Additional Study Confirms Reports of Benzene Presence, Formation in Benzoyl Peroxide Products at Room Temperature
October 7th 2024

BREAKING NEWS: Additional Study Confirms Reports of Benzene Presence, Formation in Benzoyl Peroxide Products at Room Temperature

© 2024 MJH Life Sciences

All rights reserved.